• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Home
  • Health insurance companies
  • General information
  • Privacy Policy
  • Cookie Policy
  • Diagnostics
  • Hybrid-capture
  • Driver mutations
  • Fast-track analysis for first-line treatment
  • Driver mutations in lung cancer
  • Network Genomic Medicine – Lung Cancer
  • New therapeutic approaches from genomic research
  • New immunotherapeutic therapeutic approaches
  • Molecular Diagnostics
  • Contact
  • Imprint
  • Second Opinion service
  • Service invoicing
    • For pathologists
  • Map
  • Clinical trials
    • General information
    • Lung Cancer Study Group
    • What is a clinical trial?
    • Participation in a trial
  • The Network
    • Aims
    • Funding
    • Network Genomic Medicine cancer information system (NGMcis)
    • Publications
    • Related links
    • Our team
  • Ärzte
  • Veranstaltungen
Select Page
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR Inhibitors.

 

Ortiz-Cuaran S1, Scheffler M2, Plenker D3, Dahmen I3, Scheel A4, Fernandez-Cuesta L5, Meder L4, Lovly CM6, Persigehl T7, Merkelbach-Bruse S4, Bos M8, Michels S9, Fischer R10, Albus K11, König K12, Schildhaus HU13, Fassunke J14, Ihle MA15, Pasternack H14, Heydt C16, Becker C17, Altmüller J18, Ji H19, Müller C8, Florin A4, Heuckmann JM20, Nuernberg P21, Ansén S22, Heukamp LC20, Berg J23, Pao W24, Peifer M3, Büttner R25, Wolf J26, Thomas RK3, Sos ML27..

 

Journal: Clin Cancer Res.
published: 2016 Jun 1

 

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress